Tetraphase Submits NDA for Investigational Drug for Complicated Intra-Abdominal Infections – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).
Eravacycline is a novel, fully-synthetic fluorocycline broad-spectrum antibiotic developed to treat serious, life-threatening multidrug-resistant bacterial infections and happens to be Tetraphase’s “lead product candidate.”
At the 9th IAS Conference on HIV Science, Patrick Horn, MD, PhD, chief medical officer at Tetraphase discussed with Contagion® what makes the antibiotic unique. “There are several things that make eravacycline a unique antibiotic. One of the biggest ones is its range of coverage. Even within the multidrug-resistant gram-negative pathogens, it covers most of the known resistance mechanisms,” he said. “For example, if you look at carbapenem resistance, the Amber classes A-D, some of the new antibiotics in development cover some of those, but none of them cover all, especially the metalloproteases, and eravacycline covers all of them. It covers Acinetobacter, which is also not covered well by some of the new compounds in development.”